Runben Biotechnology Co., Ltd.

XSSC:603193 Stock Report

Market Cap: CN¥9.8b

Runben Biotechnology Past Earnings Performance

Past criteria checks 5/6

Runben Biotechnology has been growing earnings at an average annual rate of 28.3%, while the Personal Products industry saw earnings growing at 7.9% annually. Revenues have been growing at an average rate of 23.8% per year. Runben Biotechnology's return on equity is 15%, and it has net margins of 24.6%.

Key information

28.3%

Earnings growth rate

8.7%

EPS growth rate

Personal Products Industry Growth7.8%
Revenue growth rate23.8%
Return on equity15.0%
Net Margin24.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Runben Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:603193 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,24730637732
30 Jun 241,19828736328
31 Mar 241,04824030927
31 Dec 231,03322630226
30 Sep 2399820929124
31 Dec 2285616025720
31 Dec 2158212115514
31 Dec 204439511011
31 Dec 1927936918

Quality Earnings: 603193 has high quality earnings.

Growing Profit Margin: 603193's current net profit margins (24.6%) are higher than last year (21%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603193's earnings have grown significantly by 28.3% per year over the past 5 years.

Accelerating Growth: 603193's earnings growth over the past year (46.3%) exceeds its 5-year average (28.3% per year).

Earnings vs Industry: 603193 earnings growth over the past year (46.3%) exceeded the Personal Products industry -6%.


Return on Equity

High ROE: 603193's Return on Equity (15%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies